ArticleScientific reports2025
Effect and mechanism of fisetin against the development of metabolic dysfunction-associated fatty liver disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent liver disease that poses a serious health threat. Fisetin (FIS) is a flavonoid compound with multiple biological activities. The aim of this study was to investigate the potential therapeutic effect of FIS on MAFLD and the underlying mechanisms through in vivo and in vitro experiments. Our results demonstrated that FIS mitigated weight gain and improved blood glucose levels, blood lipid disorder and liver steatosis in mice with high-fat diet (HFD)-induced MAFLD. RNA-seq analysis revealed that FIS affected the expression of many genes in the liver of MAFLD mice, including up-regulating the mRNA expression of Glut4 and GPx3 and down-regulating the mRNA expression of IL-1β and Cxcl10 genes. Moreover, FIS reduced sodium oleate-induced lipid accumulation, activated the GSK-3β/Nrf2/HO-1 signaling pathway, and inhibited the expression of PEPCK and G6PC in HepG2 cells. Overall, these findings demonstrate that FIS can alleviate MAFLD by enhancing the antioxidant capacity and reducing the gluconeogenic capacity in the liver, supporting FIS as a potential therapeutic against MAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.